Status: Recruiting
Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL
This prospective study was conducted to evaluate the efficacy and safety of hypofractionated radiotherapy combined with granulocyte-macrophage colony-stimulating factor, pomalidomide and glofitamab in patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma.
Participants needed: 53
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: The First Affiliated Hospital of Xiamen UniversityUpdated: Aug 6, 2026Locations: 1
Eligibility criteria
Written informed consent must be obtained before any study-related procedures. [+11]
Loss of CD20 expression in B-cell non-Hodgkin lymphoma. [+24]